HST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HST is not a strong buy right now for a beginner investor focused on long-term holding, even with $50,000-$100,000 available. The stock looks fairly priced near short-term support, but the technical trend is still weak and there is no clear upside catalyst from news or proprietary signals. My direct view: hold and wait rather than buy immediately.
The technical picture is mixed to weak. Price closed at 23.31, essentially on the S1 support level of 23.322 and just above S2 at 22.735, which suggests the stock is trying to defend support. However, the MACD histogram is -0.283 and worsening, showing bearish momentum is still active. RSI_6 at 23.518 is deeply oversold, but not yet a clean reversal signal. Moving averages are converging, which usually signals a possible inflection, but not confirmed strength. Overall, the chart is short-term weak with support nearby rather than showing a confirmed uptrend.
["Analyst targets have trended higher recently, with several firms raising price targets.", "BMO raised target to 27 and kept Outperform.", "Stifel raised target to 26.25 and kept Buy.", "Citi raised target to 24 and kept Buy.", "Options sentiment is constructive, with low put-call ratios favoring calls.", "Historical pattern data suggests upside over the next week and month."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "MACD is negative and expanding, showing bearish momentum.", "Insiders are selling, and selling increased 108.71% over the last month.", "Hedge funds are neutral with no significant accumulation trend.", "No AI Stock Picker signal today.", "No SwingMax signal recently.", "Price is still below the prior pivot level of 24.274, so the stock has not regained a stronger trend structure."]
No usable latest-quarter financial snapshot was provided because of a data error, so I cannot assess the most recent quarter’s revenue or earnings growth directly. Based on the analyst commentary, however, the lodging REIT sector had broadly better-than-expected Q1 results, with strong demand and RevPAR strength leading many companies to raise guidance. The latest quarter referenced in the analyst notes appears to be Q1 seasonally, and the tone was generally positive for operating performance.
Analyst sentiment has improved over the past month. Multiple firms raised price targets: BMO to 27, Stifel to 26.25, UBS to 23, Barclays to 23, Truist to 24, Cantor to 23, Morgan Stanley to 22, Citi to 24, and Evercore to 23. The rating mix is still split, with Buy/Outperform calls from BMO, Stifel, Truist, and Citi, while UBS, Barclays, Cantor, Morgan Stanley, and Evercore remain more neutral. Wall Street’s pros view is that RevPAR and operating performance are stronger than expected; the cons view is that valuation and sector outperformance may be ahead of fundamentals.
